Jiaying Pharmaceutical (002198.SZ) announced its third quarter report for 2024 on October 30th. The company achieved revenue of 0.26 billion yuan in the first three quarters of the year, a decrease of 31.18% year-on-year; the net income attributable to shareholders of the listed company was 2.8733 million yuan, a decrease of 88.46% year-on-year; the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -1.879 million yuan; basic earnings per share were 0.0057 yuan.
嘉应制药(002198.SZ):前三季度净利润287.33万元 同比下降88.46%
Guangdong Jiaying Pharmaceutical (002198.SZ): The net income for the first three quarters was 2.8733 million yuan, a year-on-year decrease of 88.46%.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.